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We detected Chlamydia trachomatis biovar L2 in vaginal 
swab specimens of 7 women with vaginal discharge in 
South Africa. Whole-genome sequencing directly from clini-
cal specimens identified a closely related cluster of strains. 
The clinical role of this infection in the context of syndromic 
management should be clarified.
Infection with Chlamydia trachomatis biovar L is known as lymphogranuloma venereum (LGV). This infection 
usually presents as genital ulcers, followed by an inva-
sion of the lymphatic system resulting in buboes, painful 
swelling of lymph nodes (1). In the past 2 decades, another 
manifestation of LGV has emerged in North America and 
Europe: rectal LGV infection causing proctocolitis among 
men who have sex with men (MSM) (1). In this population, 
urethral LGV also occurs (2).
There have been only sporadic reports of rectal and 
genital LGV infection in women living in the industri-
alized world (3,4). Cross-sectional studies from France, 
Switzerland, and the Netherlands did not detect biovar L 
in specimens from women with genital or rectal C. tra-
chomatis infection (1,5–7). Because lymphatic manifes-
tation has become relatively rare, LGV infection is con-
sidered an outbreak mainly among MSM in Europe and 
North America (1). Lymphatic LGV is endemic to Africa, 
but before our study, it was unknown whether C. tracho-
matis biovar L infections occurred in women in Africa. 
Thus, we determined the prevalence of this infection in 
South Africa. 
To determine whether genital C. trachomatis biovar 
L infections occur in women living in South Africa, we 
analyzed 82 DNA samples extracted from vaginal swab 
specimens that were positive by a molecular detection 
assay for C. trachomatis infection at the Department 
of Medical Microbiology at the University of Pretoria. 
The Faculty of Health Sciences Research Ethics Com-
mittee at the University of Pretoria approved the stud-
ies in which these specimens were collected. These 
swab specimens had been collected during 2012–2016 
from women attending different healthcare settings: a 
mobile health clinic in rural Mopani District (n = 52) 
and 3 departments at the academic hospital in Pretoria: 
obstetrics and gynecology clinic (n = 14), antiretroviral 
treatment clinic (n = 10), and sexually transmitted in-
fection (STI) clinic (n = 6). We assessed the presence 
of LGV in these genital specimens by using specific 
PCRs for C. trachomatis serovar L and serovar L2b (8). 
For positive PCR results, we confirmed the diagnosis 
by conducting whole-genome sequencing (WGS) of C. 
trachomatis directly from the clinical specimen as de-
scribed elsewhere (9).
Whereas C. trachomatis biovar L–specific PCR 
showed positive results for 7 specimens obtained from 
women at the antiretroviral treatment  (n = 5) and STI (n = 
2) clinics in Pretoria, we did not detect LGV in any of the 
52 specimens from women in Mopani District. All PCR test 
results for serovar L2b were negative. The 7 women with 
genital LGV all had vaginal discharge and were co-infected 
with another STI (Table).
WGS confirmed LGV (ompA sequence identical to 
those of the C. trachomatis L2 434/BU reference strain) in 
4 cases with good mean read depth (>12) and high genome 
coverage (>98%). The 4 sequences clustered well with 
the L2 sequences previously published and away from L1 
and L2b sequences. For 1 specimen, the mean read depth 
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was insufficient to allocate a biovar; insufficient DNA was 
available from 2 other samples for WGS.
This report shows emergence of C. trachomatis biovar 
L2 genital infection in women living in South Africa, a region 
to which lymphatic LGV is endemic (1). Instead of serolog-
ic analysis, we used molecular testing and WGS of clinical 
specimens to confirm the diagnosis, determine genetic relat-
edness, and identify the specific variant of genotype L. We 
observed LGV in specimens from women at the academic 
hospital in Pretoria, but not from women living in the Mopani 
District, ≈400 km away. Although the distribution of risk fac-
tors may be different, the close relatedness of LGV strains 
suggests that this might be a localized outbreak of genital C. 
trachomatis L2 infection among women living in Pretoria.
The clinical role of genital C. trachomatis biovar L 
infection in women remains to be determined. Analogous 
to non-LGV C. trachomatis infection in women and rec-
tal LGV in MSM, the clinical spectrum of genital LGV in 
women may vary from a mucosal ulcer with intrapelvic 
lymphadenopathy to cervicitis with vaginal discharge, or 
it may manifest without any symptoms at all as persistent 
asymptomatic infection. Although rectal C. trachomatis in-
fections have been reported in African women, the occur-
rence of rectal LGV is unknown (10).
The emergence of genital LGV in women poses a con-
cern in our setting, which uses syndromic management for 
STIs, because it is unclear whether the infection would be 
treated adequately with the empirical regimen of azithro-
mycin and ceftriaxone. The main limitation of this report 
is the lack of follow-up data to confirm whether syndromic 
management was effective for these biovar L C. trachoma-
tis genital infections.
In conclusion, this report shows the emergence of 
genital C. trachomatis L2 infection in South African 
women. Further research about its distribution in the gen-
eral population, clinical role, and the occurrence of rectal 
infections is warranted because it is unclear whether this 
STI is managed adequately under the current syndromic 
management guidelines.
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Table 1. Characteristics of 7 women with vaginal discharge and a positive PCR result for Chlamydia trachomatis biovar L, Pretoria, 
South Africa, 2012–2016* 
Patient 
ID 
Healthcare 
setting HIV status Co-infection C. trachomatis WGS result 
Mean read 
depth 
Genome 
coverage, % 
1 ART clinic Positive Trichomonas vaginalis L2 confirmed 41 99.5 
2 ART clinic Positive T. vaginalis L2 confirmed 12 98.3 
3 ART clinic Positive Mycoplasma genitalium L2 confirmed 21 98.6 
4 ART clinic Positive M.a genitalium L2 confirmed 72 99 
5 ART clinic Positive T. vaginalis Insufficient WGS read coverage 0.5 29 
6 STI clinic Unknown Neisseria gonorrhoeae Insufficient clinical material ND ND 
7 STI clinic Unknown N. gonorrhoeae Insufficient clinical material ND ND 
*ART, antiretroviral therapy; ID, identification; ND, not determined; STI, sexually transmitted infection; WGS, whole-genome sequencing. 
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We detected a cluster of dengue virus infections in children 
in Kenya during July 2014–June 2015. Most cases were 
serotype 1, but we detected all 4 serotypes, including co-
infections with 2 serotypes. Our findings implicate dengue 
as a cause of febrile illness in this population and highlight 
a need for robust arbovirus surveillance.
Due to lack of national surveillance programs, the ex-tent of infection with dengue viruses (DENV) among 
children is largely unknown in much of sub-Saharan Africa 
(1). Uncovering this hidden burden is critical for making 
informed public health decisions that affect populations 
that are most vulnerable to vectorborne disease. To ad-
dress this knowledge gap, in January 2014, we initiated a 
4.5-year study of the transmission and extent of arbovirus 
infection in children in Kenya. Although the study contin-
ues through June 2018, we identified a cluster of DENV 
infections among febrile children in western Kenya, prompt-
ing this report to raise awareness of DENV as a cause of 
acute febrile illness (AFI) among children in this country.
We describe results from a cohort of children with AFI 
who came to 1 of 2 regional health centers that serve the 
communities of Chulaimbo (a rural village) and Kisumu 
(an urban city), both located in western Kenya. The cohort 
is part of a larger ongoing parent study that enrolls addi-
tional child cohorts at other study sites or with other study 
designs and collects vector and environmental data. Details 
of the parent study are beyond the scope of this report and 
will be described elsewhere. The study is being conducted 
under the supervision of the institutional review board of 
Stanford University (Stanford, CA, USA; IRB-31488) and 
the scientific and ethics review unit of the Kenya Medical 
Research Institute (Kisumu, Kenya; SSC 2611). 
For this study, we enrolled febrile children 1–17 years 
of age. At the enrollment and 1-month follow-up visits, we 
collected information on demographics and risk factors, 
performed a physical examination, and obtained blood 
samples. We tested the blood samples for DENV RNA by 
reverse transcription PCR (RT-PCR) (2).
We enrolled 1,258 children with AFI during January 
2014–April 2016. We tested blood samples from 1,104 study 
participants (87.8%) by RT-PCR. Of those, 82 (7.4%) were 
positive for DENV RNA: 58 (70%) were serotype 1 (DENV-
1), 2 (2.4%) were serotype 2 (DENV-2), 13 (15.9%) were se-
rotype 3 (DENV-3), and 2 (2.4%) were serotype 4 (DENV-4) 
(Figure). We also detected co-infection with 2 serotypes in 6 
participants: 2 children had DENV-1 and -3; 3 children had 
DENV-1 and -4; and 1 child had DENV-2 and -3.
Most DENV cases occurred during July 2014–June 
2015. The likelihood of testing positive for DENV by PCR 
did not differ by age or sex. The median age of DENV PCR-
positive participants was 3.5 years (IQR 2.0–5.2 years); 
43.9% of participants were female. We did observe a higher 
likelihood of testing positive by PCR for children from the 
rural site, Chulaimbo (9.6%), compared with those from 
the urban site, Kisumu (5.8%) (p = 0.017 by Fisher exact 
test; odds ratio 1.97, 95% CI 1.14–3.43, adjusted for age 
and sex). Continued surveillance is needed to investigate 
whether DENV is endemic to these areas and if there are 
differences in regional endemicity.
Although reports of DENV infection in Kenya remain 
sparse, several sero-epidemiologic studies have produced 
evidence of DENV transmission by demonstrating serum 
DENV IgG in patients of all ages (3–6). In 2013, an out-
break of DENV-2 in Mombasa was detected, in part, by RT-
PCR (7). More recently, DENV infections were described in 
43 adult patients with fever who resided in Mtwapa, on the 
coast of Kenya near Mombasa; these cases occurred Febru-
ary 2014–January 2015 (8), which overlapped with the pe-
riod in which we observed the DENV cases we report in this 
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